scholarly journals 1466Vitamin D status before, during and after treatment and ovarian cancer survival

2021 ◽  
Vol 50 (Supplement_1) ◽  
Author(s):  
Tanya Ross ◽  
Penny Webb ◽  
Rachel Neale
Keyword(s):  
Ovarian Cancer ◽  
Vitamin D ◽  
Survival Data ◽  
Cancer Survival ◽  
Cox Regression ◽  
Primary Treatment ◽  
Parametric Models ◽  
Cancer Prognosis ◽  
Ovarian Cancer Survival ◽  
Ovarian Cancer Prognosis

Abstract Background Previous work found higher serum 25-hydroxyvitamin D (25(OH)D) [circulating form of vitamin D] concentrations at diagnosis were associated with longer survival in patients with ovarian cancer (OvCa). There was no evidence for an association with 25(OH)D after primary treatment, but power was limited. Our aim was to reassess this association in a larger sample, including measures collected during treatment and using techniques to deseasonalise 25(OH)D. Methods Participants were diagnosed between 2002-2006 and 2012-2015 from the Australian Ovarian Cancer Study (AOCS) and the Ovarian Cancer, Prognosis and Lifestyle (OPAL) study, respectively. 25(OH)D concentrations were available for 676 at diagnosis (AOCS), 805 during treatment (AOCS:208; OPAL:597) and 861 after completion of primary treatment and before recurrence (AOCS:342; OPAL:519); 1006 AOCS samples were included in the previous analysis. Sociodemographic, diet and lifestyle data came from questionnaires self-completed at recruitment, and clinical/survival data from medical records, supplemented with National Death Index linkage. We will use Cox regression and non-parametric models to examine associations with survival. Results Median 25(OH)D concentrations were lowest during treatment, intermediate at diagnosis and highest after treatment (AOCS 51, 64, and 71 nmol/L, respectively). 5-year survival was 50% in AOCS and 59% in OPAL. Updated survival results will be presented. Conclusions If the association is confirmed in this updated analysis, then increasing vitamin D concentrations may provide a way to improve survival following OvCa. Key messages Higher circulating vitamin D concentrations may improve survival in OvCa.

scholarly journals Kallikrein-Related Peptidase 3(KLK3/PSA) Single Nucleotide Polymorphisms and Ovarian Cancer Survival

2011 ◽  
Vol 14 (4) ◽  
pp. 323-327 ◽  
Author(s):  
Tracy A. O'Mara ◽  
Christina M. Nagle ◽  
Jyotsna Batra ◽  
Mary-Anne Kedda ◽  
Judith A. Clements ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Single Nucleotide Polymorphisms ◽  
Cancer Survival ◽  
Cox Regression ◽  
Prognostic Significance ◽  
Rare Allele ◽  
Nucleotide Polymorphisms ◽  
Single Nucleotide ◽  
Tumour Metastasis ◽  
Ovarian Cancer Survival

There is substantial evidence suggesting a role for hormone-regulated kallikrein-related peptidases (KLKs) in carcinogenesis and tumour metastasis. KLKs are considered to have potential as prognostic biomarkers for hormone dependent cancers, particularly ovarian cancer. The purpose of this study was to evaluate the association between Kallikrein-related peptidase 3 (KLK3) gene single nucleotide polymorphisms (SNPs) located in hormone response elements and ovarian cancer survival. DNA samples were analyzed from 304 Australian women diagnosed with epithelial ovarian cancer. The KLK3 rs266882 and rs11084033 SNPs were genotyped by the Sequenom iPLEX Mass Array platform. Hazard ratios (HR) and 95% confidence intervals (CI) were estimated using Cox regression models. An association was observed with ovarian cancer survival for homozygote carriers of the rare allele of rs11084033 (adjusted HR 2.12, 95% CI 1.08–4.15). This finding is consistent with bioinformatic analysis predicting the rs11084033 rare allele to be responsible for the loss of a confirmed androgen response element, and with published expression data suggesting that aggressive ovarian cancers show decreased KLK3 tumor expression. The rs11084033 has potential prognostic significance in ovarian cancer. However, this finding requires replication, and further investigation regarding the functional significance of rs11084033 and correlated SNPs.

When will I feel normal again? Quality of life trajectories after first-line chemotherapy for ovarian cancer.

2018 ◽  
Vol 36 (7_suppl) ◽  
pp. 172-172
Author(s):  
Penelope M Webb ◽  
Vanessa Beesley ◽  
Christina Nagle ◽  
Peter T. Grant ◽  
Anna deFazio ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Ovarian Cancer ◽  
General Population ◽  
Primary Treatment ◽  
Cancer Prognosis ◽  
Life Trajectories ◽  
Platinum Based Chemotherapy ◽  
Ovarian Cancer Prognosis ◽  
Over Time

172 Background: Patients often ask if/when they will feel normal again following treatment for ovarian cancer (OC). There is a paucity of data on the trajectories of quality of life (QoL), physical (PWB), social (SWB), emotional (EWB) and functional (FWB) wellbeing over time following chemotherapy and especially regarding those who have persistent problems. Our aim was to quantify the proportion of women with significantly lower QoL/wellbeing than the general population at the end of treatment and determine if/when they return to normal. Methods: The OPAL (Ovarian cancer Prognosis & Lifestyle) Study is a prospective study of Australian women diagnosed with invasive OC from 2012-15 who agreed to complete regular questionnaires after diagnosis. 580 participants who received ≥3 cycles of platinum-based chemotherapy as primary treatment and completed a questionnaire while on or < 6 weeks after completing chemotherapy (baseline) were included. FACT-G data came from questionnaires at baseline and ~3, 6, 9 & 18 months post-baseline. Group-based trajectory models were used to identify groups with distinct patterns of QoL/wellbeing over time. Results: Overall, 44% (254) of women had QoL scores significantly lower than the general population at baseline; 35% (88) returned to normal by 3 months after treatment, 73% by 6 months and 27% (69) had not returned to normal by 18 months. The Table shows the comparable figures for the wellbeing subscales. Conclusions: While > 50% of women with OC can expect similar QoL, FWB and EWB to the general population at the end of chemotherapy, PWB was compromised in 3 of 4 women. For most, wellbeing recovered within 6 months but a substantial proportion reported ongoing deficits. A particularly prolonged impact was seen for those with poor EWB at baseline, warranting early intervention in this subset. [Table: see text]

The influence of reproductive and hormonal factors on ovarian cancer survival

2008 ◽  
Vol 18 (3) ◽  
pp. 407-413 ◽  
Author(s):  
C. M. Nagle ◽  
C. J. Bain ◽  
A. C. Green ◽  
P. M. Webb
Keyword(s):  
Systematic Review ◽  
Ovarian Cancer ◽  
Cancer Survival ◽  
Cox Regression ◽  
Population Based ◽  
Hazard Ratios ◽  
History Of ◽  
Hormonal Exposures ◽  
Ovarian Cancer Survival ◽  
Invasive Epithelial Ovarian Cancer

Reproductive and hormonal exposures are known to influence ovarian carcinogenesis, but little is known about the effect of these factors on survival. We have studied survival according to hormonal and reproductive history in a population-based cohort of 676 Australian women aged 18–79, newly diagnosed with invasive epithelial ovarian cancer in the early 1990s. In order to place our findings in context, we have also undertaken a systematic review of the pertinent literature. Detailed information about each woman's reproductive and contraceptive history was obtained from pregnancy and contraceptive calendars at the time of diagnosis. Cox regression was used to obtain multivariate adjusted hazard ratios (HR) and 95% confidence intervals (CI). A total of 419 (62%) of the 676 women died during the follow-up (giving a 5-year survival proportion of 44%). Apart from better survival for women who had ever breastfed (multivariate HR 0.74, 95% CI 0.55–0.98), we found no association between survival from invasive ovarian cancer and a range of hormonal and gynecological factors including parity, use of oral contraceptives, and histories of tubal sterilization or hysterectomy. Systematic review of the literature generally supported the lack of influence of these factors on survival from ovarian cancer. We conclude that, except for a possible survival advantage among women with a history of breastfeeding, reproductive and hormonal exposures prior to diagnosis do not influence survival from invasive ovarian cancer, in contrast to their substantial effects on etiology of this disease

scholarly journals 680NSAID use and ovarian cancer survival

2021 ◽  
Vol 50 (Supplement_1) ◽  
Author(s):  
Azam Majidi ◽  
Renhua Na ◽  
Susan Jordan ◽  
Andreas Obermair ◽  
Penelope M Webb
Keyword(s):  
Ovarian Cancer ◽  
Cancer Survival ◽  
Proportional Hazards ◽  
Controlled Trial ◽  
Progression Free Survival ◽  
Primary Treatment ◽  
Cox Proportional Hazards ◽  
Frequent Users ◽  
Dose Aspirin ◽  
Ovarian Cancer Survival

Abstract Background Observational studies have reported survival benefits associated with non-steroidal anti-inflammatory drugs (NSAIDs), including aspirin, and non-aspirin NSAIDs (NA-NSAIDs), especially new use post-diagnosis, in women with ovarian cancer (OC). Methods Participants were women aged 18-79 diagnosed with OC in Australia, 2012-2015. Information was gathered through self-completed 3-monthly questionnaires and prescription records. Exposure was defined as any use (NA-NSAIDs/regular-dose aspirin □1/week or daily low-dose aspirin) during the year pre-diagnosis and first year post-diagnosis. We measured overall survival from start of primary treatment (surgery/neoadjuvant chemotherapy) (pre-diagnosis use) or from 12 months after the start of therapy (post-diagnosis) until the earliest of date of death/last follow-up/5 years. Cox proportional hazards regression was used to estimate survival. We also applied inverse-probability of treatment weighting (IPTW), which balances comparison groups regarding potential confounders. Results We observed improved survival associated with pre-diagnosis use of aspirin/NA-NSAIDs ≥4 days/week (frequent-users) compared to &lt; 1/week (hazard ratio [HR] =0.72, 95% confidence interval [CI]=0.54-0.97). The association was close to null for those who used medications 1-3 days/week. Similarly, we saw a 30-40% improvement in survival associated with post-diagnosis aspirin/NA-NSAID use, again driven by frequent users (HR = 0.61, 95%CI=0.42-0.88). Results were similar when we excluded pre-diagnosis users, restricted to women who received chemotherapy, or assessed cancer-specific and progression-free survival. Results from IPTW models were similar to adjusted models. Conclusions Our findings suggest aspirin/NA-NSAID use might improve survival in women with OC. Larger cohorts or, preferably, a randomised controlled trial could clarify these findings. Key messages Use of aspirin/NA-NSAIDs may improve OC survival.

scholarly journals 647Use of menopausal hormone therapy before and after ovarian cancer diagnosis and ovarian cancer survival

2021 ◽  
Vol 50 (Supplement_1) ◽  
Author(s):  
Nina Renhua Na ◽  
Susan J Jordan ◽  
Andreas Obermair ◽  
Penelope M Webb ◽  
Keyword(s):  
Ovarian Cancer ◽  
Propensity Score ◽  
Hormone Therapy ◽  
Cancer Survival ◽  
Menopausal Hormone Therapy ◽  
Cancer Prognosis ◽  
Confounding By Indication ◽  
Menopausal Women ◽  
Post Menopausal ◽  
Ovarian Cancer Survival

Abstract Background Menopausal hormone therapy (MHT) use before ovarian cancer (OvCa) diagnosis has been suggested to improve survival but data on type, duration and use after treatment for OvCa are scarce. Methods We investigated MHT use and OvCa survival among participants with newly diagnosed OvCA in the Ovarian cancer Prognosis And Lifestyle (OPAL) Study. Analysis of pre-diagnosis use was restricted to 661 post-menopausal women and analysis of post-diagnosis use included 254 women aged ≤55-years. We used multivariable Cox proportional hazards regression to estimate hazard ratios (HR) and 95% confidence intervals (CI) for the association between MHT and OvCa-specific survival. We used propensity score-based approaches to account for potential bias due to confounding by indication. Results Approximately 14% of post-menopausal women were current/recent users of oestrogen-only (7%) or oestrogen-progestin/unknown MHT (E-P=7%) at the time of diagnosis. In the pre-diagnosis analysis, E-P use was associated with better survival (HR = 0.60, 95%CI=0.37-0.98; HR = 0.93, 95%CI=0.79-1.09 per 5-years/use). The association between oestrogen-only MHT and survival was weaker and non-significant (HR = 0.74, 95%CI=0.47-1.16). Among women ≤55-years at diagnosis, the HR was 0.91 (95%CI=0.50-1.67) for new use after diagnosis regardless of type; and 0.89 (95%CI 0.51-1.54) for any use post-diagnosis compared to never users. Propensity-score-based methods showed similar estimates. Conclusions Pre-diagnosis MHT use is associated with better ovarian cancer survival. Post-diagnosis MHT use might also improve survival for women younger than 55-years, even after accounting for bias due to confounding by indication. Key messages Menopausal hormone therapy may be considered to manage menopausal symptoms in women with ovarian cancer.

Vaginal hysterectomy with or without bilateral salpingo-oophorectomy may be an alternative treatment for endometrial cancer patients with medical co-morbidities precluding standard surgical procedures: a systematic review

2019 ◽  
Vol 29 (2) ◽  
pp. 299-304 ◽  
Author(s):  
Arnold-Jan Kruse ◽  
Henk G ter Brugge ◽  
Harm H de Haan ◽  
Hugo W Van Eyndhoven ◽  
Hans W Nijman
Keyword(s):  
Ovarian Cancer ◽  
Endometrial Cancer ◽  
Vaginal Hysterectomy ◽  
Cancer Survival ◽  
Survival Rates ◽  
Survival Outcomes ◽  
Ovarian Malignancy ◽  
Post Menopausal ◽  
Ovarian Cancer Survival ◽  
Overall Survival Rates

ObjectiveVaginal hysterectomy with bilateral salpingo-oophorectomy may be an alternative strategy for patients with low-risk endometrial cancer and medical co-morbidities precluding laparoscopic or abdominal procedures. The current study evaluates the prevalence of co-existent ovarian malignancy in patients with endometrial cancer and the influence of bilateral salpingo-oophorectomy on survival outcomes in these patients.MethodsMedline and EMBASE were searched for studies published between January 1, 2000 and November 20, 2017 that investigated (1) the prevalence of co-existing ovarian malignancy (either metastases or primary synchronous ovarian cancer in women with endometrial cancer, and (2) the influence of bilateral salpingo-oophorectomy on recurrence and/or survival rates.ResultsOf the pre-menopausal and post-menopausal patients (n=6059), 373 were identified with metastases and 106 were identified with primary synchronous ovarian cancer. Of the post-menopausal patients (n=6016), 362 were identified with metastases and 44 were identified with primary synchronous ovarian cancer. Survival outcomes did not differ for pre-menopausal patients with endometrial cancer with and without bilateral salpingo-oophorectomy (5-year overall survival rates were 89–94.5% and 86–97.8%, respectively).ConclusionBilateral salpingo-oophorectomy during vaginal hysterectomy seems to have a limited impact on disease outcome in patients with endometrial cancer. These results support the view that vaginal hysterectomy alone or with bilateral salpingo-oophorectomy may be an option for patients with endometrial cancer who are not ideal surgical candidates.

Ambient air pollution and ovarian cancer survival in California

2021 ◽  
Author(s):  
Carolina Villanueva ◽  
Jenny Chang ◽  
Argyrios Ziogas ◽  
Robert E. Bristow ◽  
Verónica M. Vieira
Keyword(s):  
Ovarian Cancer ◽  
Air Pollution ◽  
Cancer Survival ◽  
Ambient Air ◽  
Ambient Air Pollution ◽  
Ovarian Cancer Survival

Usual Adult Body Mass Index Is Not Predictive of Ovarian Cancer Survival

2007 ◽  
Vol 16 (3) ◽  
pp. 626-628 ◽  
Author(s):  
Kirsten B. Moysich ◽  
Julie A. Baker ◽  
Ravi J. Menezes ◽  
Vijayvel Jayaprakash ◽  
Kerry J. Rodabaugh ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Body Mass Index ◽  
Body Mass ◽  
Cancer Survival ◽  
Adult Body Mass ◽  
Adult Body ◽  
Adult Body Mass Index ◽  
Ovarian Cancer Survival

Disparity of ovarian cancer survival between urban and rural settings

2021 ◽  
Vol 162 ◽  
pp. S137-S138
Author(s):  
Keely Ulmer ◽  
Nicholas Cardillo ◽  
Megan McDonald ◽  
David Bender ◽  
Michael Goodheart ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Survival ◽  
Rural Settings ◽  
Ovarian Cancer Survival

scholarly journals A Novel Defined Risk Signature of the Ferroptosis-Related Genes for Predicting the Prognosis of Ovarian Cancer

2021 ◽  
Vol 8 ◽  
Author(s):  
Ying Ye ◽  
Qinjin Dai ◽  
Shuhong Li ◽  
Jie He ◽  
Hongbo Qi
Keyword(s):  
Ovarian Cancer ◽  
High Risk ◽  
Risk Model ◽  
Cox Regression ◽  
Ovarian Tissue ◽  
Gene Signature ◽  
High Risk Group ◽  
Cancer Prognosis ◽  
Consensus Clustering ◽  
Gynecologic Tumor

Ferroptosis is an iron-dependent, regulated form of cell death, and the process is complex, consisting of a variety of metabolites and biological molecules. Ovarian cancer (OC) is a highly malignant gynecologic tumor with a poor survival rate. However, the predictive role of ferroptosis-related genes in ovarian cancer prognosis remains unknown. In this study, we demonstrated that the 57 ferroptosis-related genes were expressed differently between ovarian cancer and normal ovarian tissue, and based on these genes, all OC cases can be well divided into 2 subgroups by applying consensus clustering. We utilized the least absolute shrinkage and selection operator (LASSO) cox regression model to develop a multigene risk signature from the TCGA cohort and then validated it in an OC cohort from the GEO database. A 5-gene signature was built and reveals a favorable predictive efficacy in both TCGA and GEO cohort (P &lt; 0.001 and P = 0.03). The GO and KEGG analysis revealed that the differentially expressed genes (DEGs) between the low- and high-risk subgroup divided by our risk model were associated with tumor immunity, and lower immune status in the high-risk group was discovered. In conclusion, ferroptosis-related genes are vital factors predicting the prognosis of OC and could be a novel potential treatment target.

Sign in / Sign up

Export Citation Format

Share Document